Inari Medical (Inari Medical) EBIT per Share : $-0.18 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inari Medical EBIT per Share?

Inari Medical's EBIT per Share for the three months ended in Mar. 2024 was $-0.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.18.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Inari Medical's EBIT per Share or its related term are showing as below:

NARI's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Inari Medical's EBIT for the three months ended in Mar. 2024 was $-16.0 Mil.

Inari Medical EBIT per Share Historical Data

The historical data trend for Inari Medical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical EBIT per Share Chart

Inari Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.01

0.29

0.20

-0.49

0.08

Inari Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.02	0.05	0.10	-0.05	-0.28

Inari Medical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Inari Medical's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4.442	/	56.771
=	0.08

Inari Medical's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-16.009	/	57.938
=	-0.28

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18

Inari Medical (NAS:NARI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Inari Medical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Inari Medical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Inari Medical (Inari Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

IM7:Germany

Address

6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618

Website

https://www.inarimedical.com

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.

Executives

William Hoffman	director, officer: President and CEO	C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill,	officer: Chief Financial Officer	1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes	officer: Chief Operating Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu	officer: Chief Medical Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese	director	7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers	director	3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a.	10 percent owner	NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v.	10 percent owner	NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB